Watch the on-demand webinar hosted by Matthew Ostroff who will discuss vascular access for the COVID-19 patient.
EMED
Description
Watch the on-demand webinar hosted by Matthew Ostroff who will discuss vascular access for the COVID-19 patient.
Description
The study involved 100 patients and was conducted using Sonosite’s M-Turbo® ultrasound systems.
The results showed that in 85 of 100 cases (85%) USGPIVs eliminated the need for CVC placement in patients with problematic IV access. These patients also had zero complications during the follow-up period.3 When you consider an approximate 15% complication rate for CVC procedures, the use of USGPIVs could lower rates to 2.25%. With the cost of each CVC complication ranging from approximately $15,000 to $50,000, greater use of USGPIVs can mean enhanced patient safety and a significant reduction in emergency department healthcare costs.